Master of Pharmacy

World Leaders in Medically Integrated Oncology Set to Gather at NCODA's 2023 Summit to Further Elevate Patient Care

Retrieved on: 
Monday, October 23, 2023

ORLANDO, Fla., Oct. 23, 2023 /PRNewswire/ -- Physicians, nurses, pharmacists, and other important clinical and administrative team members, along with partnering pharmaceutical industry representatives from all over the world will gather in Orlando October 25-27 for the NCODA 2023 International Fall Summit to advance best practices and innovations in integrated cancer care. At the heart of the conference is the impact of medically integrated oncology and how coordination of care through a team of professionals is designed to ease the burden on patients and ensure that they feel supported and are receiving the best possible care from a wide range of oncology specialists.

Key Points: 
  • World Leaders in Medically Integrated Oncology Set to Gather at NCODA's 2023 Summit to Further Elevate Patient Care.
  • These leaders hail from a wide range of locations and healthcare systems, including Croatia, Morocco, Brazil, Japan, Canada, Sweden, and Greece.
  • Collaborating is at the heart of oncology and the integrated model, and the NCODA IEC is an example of that in practice."
  • It's an honor to work with the IEC and shine added focus on the collaboration of the international oncology pharmacist community in positively impacting patient care and clinical outcomes."

Azzur Group Appoints Senior Executive, Sarah Stevens, Ph.D., as President of Azzur Labs & Azzur Cleanrooms on Demand™

Retrieved on: 
Tuesday, September 26, 2023

In this new role, Sarah is responsible for operations and strategy across all Azzur Labs and Azzur COD locations throughout the United States.

Key Points: 
  • In this new role, Sarah is responsible for operations and strategy across all Azzur Labs and Azzur COD locations throughout the United States.
  • "I'm thrilled to join the team at Azzur Group, and I look forward to working alongside the talented and innovative people that make Azzur Labs and Azzur Cleanrooms on Demand such unique businesses," said Sarah.
  • Sarah joins Azzur Group with 20 years of industry experience, serving most recently as the Senior Vice President, Head of Early Development, Quotient Sciences.
  • "I'm pleased to welcome Sarah Stevens as the new President of Azzur Labs and Azzur Cleanrooms on Demand," said Ryan Ott , Chief Operating Officer, of Azzur Group.

Prescient Announces Recent Senior Appointments to Its Medical Team

Retrieved on: 
Wednesday, March 29, 2023

LONDON, March 29, 2023 /PRNewswire/ -- Prescient, a biopharma product and portfolio strategy firm, has announced the recent appointments of Navi Singh Parmar, Michaela Scheiner, and Dr. Sanam Sikander-Rehman as leaders in Prescient Medical.

Key Points: 
  • Prescient hires three new senior members to support its growing Medical Center of Excellence.
  • LONDON, March 29, 2023 /PRNewswire/ -- Prescient, a biopharma product and portfolio strategy firm, has announced the recent appointments of Navi Singh Parmar, Michaela Scheiner, and Dr. Sanam Sikander-Rehman as leaders in Prescient Medical.
  • At Prescient, Navi assists both Commercial and Medical clients to solve strategic challenges across various therapeutic areas.
  • Michaela has successfully supported medical education, strategy and information, functional design and medical governance projects.

Brand Institute Promotes Mark Ghobry to Divisional President, Western Europe & Emerging Markets

Retrieved on: 
Wednesday, March 15, 2023

MIAMI, March 15, 2023 /PRNewswire/ -- Brand Institute, the world's #1 naming agency and the global leader in pharmaceutical and healthcare-related name development, is proud to announce the promotion of Mark Ghobry, MPharm, to the role of Divisional President, Western Europe & Emerging Markets.

Key Points: 
  • MIAMI, March 15, 2023 /PRNewswire/ -- Brand Institute, the world's #1 naming agency and the global leader in pharmaceutical and healthcare-related name development, is proud to announce the promotion of Mark Ghobry, MPharm, to the role of Divisional President, Western Europe & Emerging Markets.
  • "Whilst the UK and Nordic region continues to thrive in the pharma and biotech sectors, we have seen enormous growth in some emerging markets, like India," commented Mr. Ghobry.
  • "As Divisional President, I look forward to working with our leadership team to provide innovative and distinguished services to our clients."
  • "We're excited to have him leading the effort to bolster and expand our reach throughout Western Europe and emerging markets."

NCODA International Executive Council to Advance Medically Integrated Oncology Worldwide

Retrieved on: 
Thursday, March 9, 2023

CAZENOVIA, N.Y., March 9, 2023 /PRNewswire/ -- NCODA a non-profit organization whose Mission is to empower the medically-integrated oncology team to deliver positive, patient-centered outcomes is proud to announce the formation of its International Executive Council (IEC).

Key Points: 
  • CAZENOVIA, N.Y., March 9, 2023 /PRNewswire/ -- NCODA a non-profit organization whose Mission is to empower the medically-integrated oncology team to deliver positive, patient-centered outcomes is proud to announce the formation of its International Executive Council (IEC).
  • The IEC will provide insight and leadership to NCODA regarding meeting the ever-changing needs of oncology patients and healthcare professionals around the world.
  • NCODA is a leading non-profit organization (NY, USA) dedicated to improving the quality of cancer care and promoting the highest standards in the field of oncology practice.
  • For more information about NCODA and the International Executive Council, please visit www.ncoda.org .

NCODA International Executive Council to Advance Medically Integrated Oncology Worldwide

Retrieved on: 
Thursday, March 9, 2023

CAZENOVIA, N.Y., March 9, 2023 /PRNewswire/ -- NCODA a non-profit organization whose Mission is to empower the medically-integrated oncology team to deliver positive, patient-centered outcomes is proud to announce the formation of its International Executive Council (IEC).

Key Points: 
  • CAZENOVIA, N.Y., March 9, 2023 /PRNewswire/ -- NCODA a non-profit organization whose Mission is to empower the medically-integrated oncology team to deliver positive, patient-centered outcomes is proud to announce the formation of its International Executive Council (IEC).
  • The IEC will provide insight and leadership to NCODA regarding meeting the ever-changing needs of oncology patients and healthcare professionals around the world.
  • NCODA is a leading non-profit organization (NY, USA) dedicated to improving the quality of cancer care and promoting the highest standards in the field of oncology practice.
  • For more information about NCODA and the International Executive Council, please visit www.ncoda.org .

Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality

Retrieved on: 
Sunday, January 22, 2023

Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality

Key Points: 
  • Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality
    PARIS, France, January 4th, 2023, 08:30 am CET – Pharnext SA (FR001400BV89 - ALPHA) (the “Company”), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today announces the appointment of Scott Johnson as VP, Head of Quality.
  • Prior to Oyster, Scott served as Director, Quality Assurance at Lupin Pharmaceuticals where he had overall responsibility for quality and compliance.
  • Hugo Brugière, Chairman and Chief Executive Officer of Pharnext, commented: “I look forward to working with Scott and am delighted to welcome him to the Pharnext Senior Leadership Team.

ONL Therapeutics Appoints Sushanta Mallick as Chief Development Officer

Retrieved on: 
Wednesday, February 9, 2022

ANN ARBOR, Mich., Feb. 09, 2022 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the appointment of Sushanta Mallick, PhD, MBA, to the newly created position of Chief Development Officer.

Key Points: 
  • ANN ARBOR, Mich., Feb. 09, 2022 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the appointment of Sushanta Mallick, PhD, MBA, to the newly created position of Chief Development Officer.
  • Sushantas experience in leading ophthalmology development, particularly in our target disease areas of interest, will be critical as we continue to advance ONL1204 across three key indications, said David Esposito, Chief Executive Officer of ONL Therapeutics.
  • I am thrilled to join the ONL Therapeutics team with its mission of bringing neuroprotection innovation to patients suffering from serious retinal diseases, commented Dr. Mallick.
  • ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to protecting and improving the vision of patients with retinal disease.

The Complexities of Pediatric Rare Disease Clinical Trials: Regulatory and Operational Strategies for Success, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, February 7, 2022

TORONTO, Feb. 7, 2022 /PRNewswire-PRWeb/ --Strategic planning and execution are crucial when implementing rare disease clinical trials, especially when factoring in the added complexities of pediatric rare disease trials.

Key Points: 
  • TORONTO, Feb. 7, 2022 /PRNewswire-PRWeb/ --Strategic planning and execution are crucial when implementing rare disease clinical trials, especially when factoring in the added complexities of pediatric rare disease trials.
  • There are many operational and regulatory challenges to consider when planning for pediatric rare disease clinical trials, including recruitment, elevated regulatory scrutiny, blood volume restrictions and supply chain logistics.
  • Attend this webinar with Medpace experts on Rare Disease Day 2022 as they share operational and regulatory challenges associated with pediatric rare disease clinical trials, along with strategies to help anticipate and overcome them.
  • For more information, or to register for this event, visit The Complexities of Pediatric Rare Disease Clinical Trials: Regulatory and Operational Strategies for Success.

Oncocyte Appoints Gisela A. Paulsen as Chief Operating Officer

Retrieved on: 
Thursday, October 7, 2021

We believe that Giselas years of driving focused, strategic growth will be instrumental in strengthening and expanding our existing capabilities and maximizing new opportunities as a leader in precision oncology diagnostics and monitoring, said Ron Andrews, President and Chief Executive Officer of Oncocyte.

Key Points: 
  • We believe that Giselas years of driving focused, strategic growth will be instrumental in strengthening and expanding our existing capabilities and maximizing new opportunities as a leader in precision oncology diagnostics and monitoring, said Ron Andrews, President and Chief Executive Officer of Oncocyte.
  • Gisela has an incredible track record of servant leadership, and I am confident that her alignment with our Company vision and culture will create sustainable, long-term success for the entire Oncocyte portfolio.
  • Prior to joining Oncocyte, Paulsen was most recently General Manager of Exact Sciences newly acquired Genomic Health, renamed Precision Oncology.
  • Before her time at Roche/Genentech, Paulsen was a General Manager at Health Learning Systems, the founding medical education unit of Ogilvy.